The bioanalysis of lipid nanoparticle delivery systems
As a delivery system for novel drug modalities, lipid nanoparticle systems present a new challenge for the bioanalyst.
Nucleic acid therapies are a class of genetic medicines with broad clinical application for conditions undruggable by conventional molecular scaffolds. Used to treat diverse indications, their efficacy is dependent on being able to deliver the therapy directly to cell cytoplasm as systemic delivery is typically challenging due to rapid clearance of the naked therapy by the liver and kidneys. Lipid nanoparticles (LNPs) are small packets of ionisable lipids developed to deliver nucleic acid therapies effectively and safely to their cellular targets. There is a desire to understand the exposure and distribution of LNPs as a means of developing effective nucleic acid therapies and LNP toxicity arising from localised accumulation.
To read the full article, click here
In association with:
